These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study. Kanter J; Thompson AA; Pierciey FJ; Hsieh M; Uchida N; Leboulch P; Schmidt M; Bonner M; Guo R; Miller A; Ribeil JA; Davidson D; Asmal M; Walters MC; Tisdale JF Am J Hematol; 2023 Jan; 98(1):11-22. PubMed ID: 36161320 [TBL] [Abstract][Full Text] [Related]
5. Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease. Goyal S; Tisdale J; Schmidt M; Kanter J; Jaroscak J; Whitney D; Bitter H; Gregory PD; Parsons G; Foos M; Yeri A; Gioia M; Voytek SB; Miller A; Lynch J; Colvin RA; Bonner M N Engl J Med; 2022 Jan; 386(2):138-147. PubMed ID: 34898140 [TBL] [Abstract][Full Text] [Related]
6. Gene Therapy in a Patient with Sickle Cell Disease. Ribeil JA; Hacein-Bey-Abina S; Payen E; Magnani A; Semeraro M; Magrin E; Caccavelli L; Neven B; Bourget P; El Nemer W; Bartolucci P; Weber L; Puy H; Meritet JF; Grevent D; Beuzard Y; Chrétien S; Lefebvre T; Ross RW; Negre O; Veres G; Sandler L; Soni S; de Montalembert M; Blanche S; Leboulch P; Cavazzana M N Engl J Med; 2017 Mar; 376(9):848-855. PubMed ID: 28249145 [TBL] [Abstract][Full Text] [Related]
7. Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice. Sii-Felice K; Giorgi M; Leboulch P; Payen E Exp Hematol; 2018 Aug; 64():12-32. PubMed ID: 29807062 [TBL] [Abstract][Full Text] [Related]
8. Exagamglogene Autotemcel for Severe Sickle Cell Disease. Frangoul H; Locatelli F; Sharma A; Bhatia M; Mapara M; Molinari L; Wall D; Liem RI; Telfer P; Shah AJ; Cavazzana M; Corbacioglu S; Rondelli D; Meisel R; Dedeken L; Lobitz S; de Montalembert M; Steinberg MH; Walters MC; Eckrich MJ; Imren S; Bower L; Simard C; Zhou W; Xuan F; Morrow PK; Hobbs WE; Grupp SA; N Engl J Med; 2024 May; 390(18):1649-1662. PubMed ID: 38661449 [TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States. Herring WL; Gallagher ME; Shah N; Morse KC; Mladsi D; Dong OM; Chawla A; Leiding JW; Zhang L; Paramore C; Andemariam B Pharmacoeconomics; 2024 Jun; 42(6):693-714. PubMed ID: 38684631 [TBL] [Abstract][Full Text] [Related]
10. Potentially therapeutic levels of anti-sickling globin gene expression following lentivirus-mediated gene transfer in sickle cell disease bone marrow CD34+ cells. Urbinati F; Hargrove PW; Geiger S; Romero Z; Wherley J; Kaufman ML; Hollis RP; Chambers CB; Persons DA; Kohn DB; Wilber A Exp Hematol; 2015 May; 43(5):346-351. PubMed ID: 25681747 [TBL] [Abstract][Full Text] [Related]
11. Post-Transcriptional Genetic Silencing of Esrick EB; Lehmann LE; Biffi A; Achebe M; Brendel C; Ciuculescu MF; Daley H; MacKinnon B; Morris E; Federico A; Abriss D; Boardman K; Khelladi R; Shaw K; Negre H; Negre O; Nikiforow S; Ritz J; Pai SY; London WB; Dansereau C; Heeney MM; Armant M; Manis JP; Williams DA N Engl J Med; 2021 Jan; 384(3):205-215. PubMed ID: 33283990 [TBL] [Abstract][Full Text] [Related]
12. LentiGlobin Administration to Sickle Cell Disease Patients: Effect on Serum Markers and Vaso-Occlusive Crisis. Kumar H; Sharma V; Wadhwa SS; Gowda DM; Kaushik S; Joseph AM; Karas M; Quinonez J; Furiato A Cureus; 2024 Jan; 16(1):e51881. PubMed ID: 38327940 [TBL] [Abstract][Full Text] [Related]
13. CRISPR-Cas9 Editing of the Sharma A; Boelens JJ; Cancio M; Hankins JS; Bhad P; Azizy M; Lewandowski A; Zhao X; Chitnis S; Peddinti R; Zheng Y; Kapoor N; Ciceri F; Maclachlan T; Yang Y; Liu Y; Yuan J; Naumann U; Yu VWC; Stevenson SC; De Vita S; LaBelle JL N Engl J Med; 2023 Aug; 389(9):820-832. PubMed ID: 37646679 [TBL] [Abstract][Full Text] [Related]
14. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study. Ferrua F; Cicalese MP; Galimberti S; Giannelli S; Dionisio F; Barzaghi F; Migliavacca M; Bernardo ME; Calbi V; Assanelli AA; Facchini M; Fossati C; Albertazzi E; Scaramuzza S; Brigida I; Scala S; Basso-Ricci L; Pajno R; Casiraghi M; Canarutto D; Salerio FA; Albert MH; Bartoli A; Wolf HM; Fiori R; Silvani P; Gattillo S; Villa A; Biasco L; Dott C; Culme-Seymour EJ; van Rossem K; Atkinson G; Valsecchi MG; Roncarolo MG; Ciceri F; Naldini L; Aiuti A Lancet Haematol; 2019 May; 6(5):e239-e253. PubMed ID: 30981783 [TBL] [Abstract][Full Text] [Related]
15. A mass spectrometry assay for detection of endogenous and lentiviral engineered hemoglobin in cultured cells and sickle cell disease mice. Wang X; McKillop WM; Dlugi TA; Faber ML; Alvarez-Argote J; Chambers CB; Wilber A; Medin JA J Gene Med; 2024 Jan; 26(1):e3567. PubMed ID: 37455676 [TBL] [Abstract][Full Text] [Related]
16. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. Howard J; Ataga KI; Brown RC; Achebe M; Nduba V; El-Beshlawy A; Hassab H; Agodoa I; Tonda M; Gray S; Lehrer-Graiwer J; Vichinsky E Lancet Haematol; 2021 May; 8(5):e323-e333. PubMed ID: 33838113 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic hemoglobin levels after gene transfer in β-thalassemia mice and in hematopoietic cells of β-thalassemia and sickle cells disease patients. Breda L; Casu C; Gardenghi S; Bianchi N; Cartegni L; Narla M; Yazdanbakhsh K; Musso M; Manwani D; Little J; Gardner LB; Kleinert DA; Prus E; Fibach E; Grady RW; Giardina PJ; Gambari R; Rivella S PLoS One; 2012; 7(3):e32345. PubMed ID: 22479321 [TBL] [Abstract][Full Text] [Related]
20. A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia. Bank A; Dorazio R; Leboulch P Ann N Y Acad Sci; 2005; 1054():308-16. PubMed ID: 16339679 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]